The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Natural history and disease progression in Chinese chronic hepatitis B patients in immune‐tolerant phase†
Open accessAbstract
UNLABELLED: In view of the findings that high hepatitis B virus (HBV) deoxyribonucleic acid (DNA) is associated with increased risk of chronic hepatitis B (CHB)-related complications, disease progression in CHB patients in the immune-tolerant phase is uncertain. We evaluated disease progression in 57 immune-tolerant CHB patients with high HBV DNA. Each subject underwent an initial liver biopsy. In those who remained in the immune-tolerant phase, a follow-up liver biopsy was performed after 5 years of follow-up. Patients who developed elevated serum alanine aminotransferase (ALT) levels were discontinued from the study after a follow-up liver biopsy. Disease progression was defined as a 1-point increase in fibrosis stage. Initial liver biopsies showed the median fibrosis stage of the study patients was 1 (range 0-1). By the end of follow-up, 9 of the 57 patients (15.8%) had developed elevated serum ALT. In those who remained in the immune-tolerant phase, follow-up fibrosis stage was comparable with the initial fibrosis stage (P = 0.58). However, disease progression was greater in patients who developed elevated serum ALT when compared with those who remained in the immune-tolerant phase (5 of 9 vs. 3 of 48, respectively, P = 0.001). The median rate of fibrosis progression of patients who remained in the immune-tolerant phase was lower than that of patients with high serum ALT (0 U/year [range -0.40-0.20 U/year] versus 0.21 U/year [range 0-1.11 U/year], respectively, P = 0.04). CONCLUSION: CHB patients in the immune-tolerant phase have mild disease. In those who remained in the immune-tolerant phase in the present study, disease progression was minimal. However, immune-tolerant patients who progressed to the immune clearance phase often faced disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Histological grading and staging of chronic hepatitis
Ishak, K., Baptista, A., Bianchi, L., Callea, F., De Groote, J., Gudat, F., Denk, H., Desmet, V., Korb, G., MacSween, R. N. M., et al. (1995) · Journal of Hepatology · doi:10.1016/0168-8278(95)80226-6 · Cited by 5,029
Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level
Chen, C.-J. (2006) · JAMA · doi:10.1001/jama.295.1.65 · Cited by 3,140
Lok, A. S. F., & McMahon, B. J. (2007) · Hepatology · doi:10.1002/hep.21513 · Cited by 3,087
Lee, W. M. (1997) · New England Journal of Medicine · doi:10.1056/nejm199712113372406 · Cited by 2,569
Castéra, L., Vergniol, J., Foucher, J., Le Bail, B., Chanteloup, E., Haaser, M., Darriet, M., Couzigou, P., & de Lédinghen, V. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.018 · Cited by 2,487
Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
Liaw, Y.-F., Sung, J. J. Y., Chow, W. C., Farrell, G., Lee, C.-Z., Yuen, H., Tanwandee, T., Tao, Q.-M., Shue, K., Keene, O. N., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033364 · Cited by 2,266
Panahi, M., Naderi, M., Morteza, T. S., & Parizadeh, S. M. J. (2007) · Cited by 1,722
Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral Load
Iloeje, U. H., Yang, H., Su, J., Jen, C., You, S., & Chen, C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.016 · Cited by 1,528
Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study
Foucher, J. (2006) · Gut · doi:10.1136/gut.2005.069153 · Cited by 1,284
Hepatitis B e Antigen and the Risk of Hepatocellular Carcinoma
Yang, H.-I., Lu, S.-N., Liaw, Y.-F., You, S.-L., Sun, C.-A., Wang, L.-Y., Hsiao, C. K., Chen, P.-J., Chen, D.-S., & Chen, C.-J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013215 · Cited by 1,222
Wong, D. K. H., Cheung, A. M., O'Rourke, K., Naylor, C. D., Detsky, A. S., & Heathcote, J. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-4-199308150-00011 · Cited by 984
Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B
Kao, J., Chen, P., Lai, M., & Chen, D. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70261-7 · Cited by 925
Hepatitis B Virus Genotype and DNA Level and Hepatocellular Carcinoma: A Prospective Study in Men
Yu, M.-W., Yeh, S.-H., Chen, P.-J., Liaw, Y.-F., Lin, C.-L., Liu, C.-J., Shih, W.-L., Kao, J.-H., Chen, D.-S., & Chen, C.-J. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji043 · Cited by 569
Yim, H. J., & Lok, A. S.-F. (2006) · Hepatology · doi:10.1002/hep.20956 · Cited by 545
A comparison of fibrosis progression in chronic liver diseases
Poynard, T., Mathurin, P., Lai, C.-L., Guyader, D., Poupon, R., Tainturier, M.-H., Myers, R. P., Muntenau, M., Ratziu, V., Manns, M., et al. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00413-0 · Cited by 474
Hui, C., Cheung, W. W. W., Zhang, H., Au, W., Yueng, Y., Leung, A. Y. H., Leung, N., Luk, J. M., Lie, A. K. W., Kwong, Y., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.04.015 · Cited by 453
Self-citationAn appraisal of the histopathological assessment of liver fibrosis
Standish, R. A., Cholongitas, E., Dhillon, A., Burroughs, A. K., & Dhillon, A. P. (2006) · Gut · doi:10.1136/gut.2005.084475 · Cited by 430
Ikeda, K., Saitoh, S., Suzuki, Y., Kobayashi, M., Tsubota, A., Koida, I., Arase, Y., Fukuda, M., Chayama, K., Murashima, N., et al. (1998) · Journal of Hepatology · doi:10.1016/s0168-8278(98)80339-5 · Cited by 428
Long-Term Remission of Chronic Hepatitis B after Alpha-Interferon Therapy
Korenman, J., Baker, B., Waggoner, J., Everhart, J. E., Di Bisceglie, A. M., & Hoofnagle, J. H. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-8-629 · Cited by 396
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States
Keeffe, E. B., Dieterich, D. T., Han, S.-H. B., Jacobson, I. M., Martin, P., Schiff, E. R., Tobias, H., & Wright, T. L. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(03)00312-4 · Cited by 359
Brunetto, M. R., Oliveri, F., Coco, B., Leandro, G., Colombatto, P., Gorin, J. M., & Bonino, F. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00266-5 · Cited by 331
Ribavirin as Therapy for Chronic Hepatitis C: A Randomized, Double-Blind, Placebo-Controlled Trial
Di Bisceglie, A. M., Conjeevaram, H. S., Fried, M. W., Sallie, R., Park, Y., Yurdaydin, C., Swain, M., Kleiner, D. E., Mahaney, K., & Hoofnagle, J. H. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-12-199512150-00001 · Cited by 328
Chu, C., Hung, S.-J., Lin, J., Tai, D., & Liaw, Y. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.12.040 · Cited by 287
Lau, G. K. K., Leung, Y.-H., Fong, D. Y. T., Au, W.-Y., Kwong, Y.-L., Lie, A., Hou, J.-L., Wen, Y.-M., Nanj, A., & Liang, R. (2002) · Blood · doi:10.1182/blood.v99.7.2324 · Cited by 233
Self-citationNatural history of hepatitis B: Epidemiology
(2010) · Hepatitis C and B · doi:10.4324/9780203357187_chapter_17 · Cited by 204
Natural history of hepatitis B
Fattovich, G. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00139-9 · Cited by 199
Hui, C., Belaye, T., Montegrande, K., & Wright, T. L. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00004-7 · Cited by 125
Self-citationHistological grading and staging in chronic hepatitis: clinical applications and problems
Hübscher, S. G. (1998) · Journal of Hepatology · doi:10.1016/s0168-8278(98)80134-7 · Cited by 93
The Maze of Treatments for Hepatitis B
Lok, A. S.-F. (2005) · New England Journal of Medicine · doi:10.1056/nejme058119 · Cited by 91
Cahen, D. L., van Leeuwen, D. J., ten Kate, F. J. W., Blok, A. P. R., Ousting, J., & Chamuleau, R. A. F. M. (1996) · Liver International · doi:10.1111/j.1600-0676.1996.tb00713.x · Cited by 25
Predicting survival in hepatitis B
Sherman, M. (2005) · Gut · doi:10.1136/gut.2005.071332 · Cited by 20
Cited by
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
Sarin, S. K., Kumar, M., Lau, G. K., Abbas, Z., Chan, H. L. Y., Chen, C. J., Chen, D. S., Chen, H. L., Chen, P. J., Chien, R. N., et al. (2016) · Hepatology International · doi:10.1007/s12072-015-9675-4 · Cited by 2,550
Self-citationAASLD guidelines for treatment of chronic hepatitis B
Terrault, N. A., Bzowej, N. H., Chang, K., Hwang, J. P., Jonas, M. M., & Murad, M. H. (2016) · Hepatology · doi:10.1002/hep.28156 · Cited by 2,006
Trépo, C., Chan, H. L. Y., & Lok, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60220-8 · Cited by 1,623
Fattovich, G., Bortolotti, F., & Donato, F. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.11.011 · Cited by 1,348
Liaw, Y.-F., & Chu, C.-M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60207-5 · Cited by 1,218
Metadata
- Authors
- Hui, C., Leung, N., Yuen, S., Zhang, H., Leung, K., Lu, L., Cheung, S. K. F., Wong, W., & Lau, G. K.
- Venue
- Hepatology
- Published
- 2007-08
- Volume
- 46
- Issue
- 2
- Pages
- 395-401
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2019596061
- Cited by
- 266
- References
- 31
- FWCI
- 12.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.